Hologic, Inc.

NasdaqGS:HOLX Rapport sur les actions

Capitalisation boursière : US$16.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Hologic Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Hologic ont diminué à un taux annuel moyen de -29.6%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 13.6% par an. Les revenus ont augmenté de en baisse à un taux moyen de 7.3% par an. Le rendement des capitaux propres de Hologic est 10.4% et ses marges nettes sont de 13.2%.

Informations clés

-29.63%

Taux de croissance des bénéfices

-26.94%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie8.90%
Taux de croissance des recettes-7.29%
Rendement des fonds propres10.37%
Marge nette13.18%
Dernière mise à jour des bénéfices27 Dec 2025

Mises à jour récentes des performances passées

Recent updates

Mise à jour du récit • Apr 10

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.
Mise à jour du récit • Mar 26

HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes

Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.
Mise à jour du récit • Mar 12

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes

Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.
Mise à jour du récit • Feb 26

HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path

Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.
Mise à jour du récit • Feb 11

HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026

Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.
Mise à jour du récit • Jan 26

HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026

Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.
Mise à jour du récit • Jan 12

HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026

Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.
Mise à jour du récit • Dec 18

HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026

We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.
Mise à jour du récit • Dec 04

HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026

The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.
Mise à jour du récit • Nov 20

HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026

Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.
Mise à jour du récit • Nov 05

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance

Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.
Mise à jour du récit • Oct 22

Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum

Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.
Mise à jour du récit • Sep 28

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.
Article d’analyse • Sep 13

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Mise à jour du récit • Sep 05

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.
Article d’analyse • Aug 04

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...
Article d’analyse • Jul 19

Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...
Article d’analyse • Jul 01

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...
Article d’analyse • Jun 13

Is Hologic (NASDAQ:HOLX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • May 06

Hologic: Soft Performance, But Cheap Enough

Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking Alpha
Seeking Alpha • Jan 17

Hologic: Reasonably, But Not Compellingly Valued

Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions.  Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking Alpha

Ventilation des recettes et des dépenses

Comment Hologic gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqGS:HOLX Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
27 Dec 254,127544995248
27 Sep 254,101566994248
28 Jun 254,0395571,056251
29 Mar 254,0275571,045253
28 Dec 244,0397441,016266
28 Sep 244,030790995273
29 Jun 243,988702985278
30 Mar 243,961467985287
30 Dec 233,969515984286
30 Sep 234,030456988294
01 Jul 234,0384841,012297
01 Apr 234,0577531,016290
31 Dec 224,4669901,045285
24 Sep 224,8631,3021,038283
25 Jun 225,2261,5121,076284
26 Mar 225,3921,5521,092288
25 Dec 215,4941,7161,040290
25 Sep 215,6321,872994276
26 Jun 215,6632,038921257
27 Mar 215,3171,907870243
26 Dec 204,5361,384827221
26 Sep 203,7761,115840223
27 Jun 203,295497845226
28 Mar 203,325453859232
28 Dec 193,38784895240
28 Sep 193,367-204897232
29 Jun 193,315-30878225
30 Mar 193,287-11882218
29 Dec 183,258-419883217
29 Sep 183,218-111915219
30 Jun 183,207-79866227
31 Mar 183,189-132853235
30 Dec 173,1161,076838233
30 Sep 173,059756819233
01 Jul 172,983765764235
01 Apr 172,894790721231
31 Dec 162,872332686235
24 Sep 162,833331676232
25 Jun 162,809264671223
26 Mar 162,785208667221
26 Dec 152,747187647215
26 Sep 152,705132624215
27 Jun 152,641135610213

Des revenus de qualité: HOLX a un important ponctuel perte de $343.6M impactant ses 12 derniers mois de résultats financiers à 27th December, 2025.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de HOLX sont inférieures à celles de l'année dernière HOLX. (13.2%) sont inférieures à celles de l'année dernière (18.4%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de HOLX ont diminué de 29.6% par an au cours des 5 dernières années.

Accélération de la croissance: HOLX a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.

Bénéfices par rapport au secteur d'activité: HOLX a enregistré une croissance négative de ses bénéfices ( -27% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Medical Equipment ( 14.8% ).

Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de HOLX ( 10.4% ) est considéré comme faible.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/04/06 21:58
Cours de l'action en fin de journée2026/04/06 00:00
Les revenus2025/12/27
Revenus annuels2025/09/27

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Hologic, Inc. est couverte par 25 analystes. 15 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
David ToungArgus Research Company
Charles ButlerBarclays
Charley JonesBarrington Research Associates, Inc.